627 related articles for article (PubMed ID: 16919005)
1. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
2. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
4. Survival with first-line bosentan in patients with primary pulmonary hypertension.
McLaughlin VV; Sitbon O; Badesch DB; Barst RJ; Black C; Galiè N; Rainisio M; Simonneau G; Rubin LJ
Eur Respir J; 2005 Feb; 25(2):244-9. PubMed ID: 15684287
[TBL] [Abstract][Full Text] [Related]
5. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
6. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
Keogh A; Strange G; McNeil K; Williams TJ; Gabbay E; Proudman S; Weintraub RG; Wlodarczyk J; Dalton B
Intern Med J; 2011 Mar; 41(3):227-34. PubMed ID: 20002851
[TBL] [Abstract][Full Text] [Related]
7. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
[TBL] [Abstract][Full Text] [Related]
9. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
11. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
14. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term bosentan in children with pulmonary arterial hypertension.
Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
[TBL] [Abstract][Full Text] [Related]
18. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
20. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
